Search

Your search keyword '"Annie Luetkemeyer"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Annie Luetkemeyer" Remove constraint Author: "Annie Luetkemeyer"
21 results on '"Annie Luetkemeyer"'

Search Results

1. Risk of COVID-19 after natural infection or vaccinationResearch in context

2. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort

3. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case

4. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

5. Tuberculosis Associated with HIV Infection

6. 448. Disproportionate Burden of COVID-19 on Latinx Residents among Hospitalized Patients at San Francisco’s Public Health Hospital

7. Localized US Efforts to Eliminate Hepatitis C

8. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

9. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

10. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

11. Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HCV Genotype 1–Infected Subjects With Insulin Resistance and Previous Nonresponse to Peginterferon and Ribavirin Therapy

12. Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study

13. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study

14. Tuberculosis as Part of the Natural History of HIV Infection in Developing Countries

15. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study

16. Antiretroviral therapy and TB

17. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

18. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

20. Clinical Presentation and Course of Acute Hepatitis C Infection in HIV-Infected Patients

21. P14: Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV co-infected patients (PHOTON-1)

Catalog

Books, media, physical & digital resources